CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
47 hedge funds and large institutions have $28M invested in CTI BioPharma Corp. (DE) Common Stock in 2017 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 17 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less capital invested
Capital invested by funds: $29.7M → $28M (-$1.71M)
19% less funds holding
Funds holding: 58 → 47 (-11)
21% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 14
35% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.64M |
| 2 |
Millennium Management
New York
|
+$527K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$246K |
| 4 |
Morgan Stanley
New York
|
+$245K |
| 5 |
Jane Street
New York
|
+$220K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.07M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$384K |
| 3 |
Goldman Sachs
New York
|
-$288K |
| 4 |
Renaissance Technologies
New York
|
-$252K |
| 5 |
CA
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
|
-$145K |
CTIC Hedge Fund Activity: Q1 2017 in Review
47 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q1 2017, worth a combined $28M — down 5.7% from $29.7M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CTIC and 11 opened new positions — a net loss of 6 holders — while 14 trimmed existing stakes and 11 added.
The largest buyer was BlackRock, opening a new position worth an estimated $1.64M. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $1.07M sold.
- 47 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q1 2017, down from 58 in Q4 2016.
- Funds reported $28M of CTI BioPharma Corp. (DE) Common Stock stock for Q1 2017, down 5.7% quarter-over-quarter.
- 11 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q1 2017 and 17 closed out, a net change of -6 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q1 2017 was BlackRock, an estimated $1.64M added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q1 2017 was Stonepine Capital Management, an estimated $1.07M sold.
Based on aggregated 13F filings for Q1 2017.